← 產業報告目錄

Chemiluminescence Immunoassay Market by Product (Instruments, Consumables), Technology (CLEIA, ECLI, Microparticle CLIA), Sample Type (Blood, Saliva), Application (Oncology, Cardiology), End User (Hospital, Clinical Laboratory) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-03-06頁數 383報告編號 MD8709

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The chemiluminescence immunoassay market is projected to reach USD 16.39 billion by 2031 from USD 11.58 billion in 2026, at a CAGR of 7.2% from 2026 to 2031. The global market for CLIA testing systems is growing as people need accurate diagnostic tests to identify chronic and infectious diseases, including cancer, cardiovascular disorders, thyroid diseases, and viral infections. The increasing need for early disease detection, together with preventive healthcare approaches, leads to greater use of CLIA testing because it provides excellent sensitivity and a wide testing range and can identify trace amounts of biomarkers. The development of automated high-throughput testing systems, together with more stable testing materials and the ability to conduct multiple tests simultaneously, has improved laboratory productivity while decreasing testing duration. The market growth benefits from improved healthcare facilities, expanded testing laboratory systems, and increased medical expenditures that emerging markets are experiencing. The rising importance of biomarker testing for personalized medicine, drug development, and clinical research, together with strict blood screening regulations and health checkup awareness, boosts the need for CLIA systems in hospitals and reference laboratories throughout the world. “Based on the product, the consumables segment is expected to grow at the highest CAGR in the CLIA market.” The consumables segment of the CLIA market is growing because diagnostic testing requires laboratories to use reagents, calibrators, controls, and reaction vessels multiple times throughout their workday. Assay kits and reagent packs that hospitals and reference laboratories use daily see increased demand because infectious disease tests, oncology marker tests, cardiac biomarker tests, endocrine disorder tests, and therapeutic drug monitoring tests are being performed more frequently. Consumables require continuous replacement, which generates ongoing revenue while driving market growth, in contrast to analyzers. The adoption of new technologies that enhance reagent stability and ready-to-use product development and extended shelf-life capabilities leads to higher operational efficiency and lower material waste in laboratory workflows. The expansion of automated high-throughput CLIA systems, together with increased preventive health screening programs, higher blood safety testing, and expanded test menu options, is driving up consumables consumption, which makes this segment a key driver of overall CLIA market expansion. “Based on application, the oncology segment is expected to grow with the highest CAGR in the CLIA market.” The CLIA market in oncology applications shows growth because cancer cases are increasing worldwide, and there is greater demand for early diagnosis, prognosis evaluation, and treatment assessment. CLIA technology enables the detection of tumor markers through highly sensitive and specific methods, which include PSA, CA-125, CEA, AFP, and HER2 as diagnostic tools for initial patient evaluation and progress assessment of their medical condition. The rise in biomarker-based testing and precision oncology practices has created a need for dependable immunoassays, which assist in determining targeted therapies and individualized treatment options. The clinical use of CLIA tests has grown because these tests now help doctors monitor patient treatment response, identify cancer recurrences, and assess patients who have a high risk of developing cancer. The introduction of better assay systems, which enhance test sensitivity through automated processes and multiplex testing features, will continue to drive businesses toward adopting CLIA systems in their cancer diagnostic processes. “Based on the end user, the hospitals segment is expected to grow by the highest CAGR in the CLIA market.” Hospitals need to conduct accurate tests for various medical conditions, including cardiac markers, sepsis indicators, cancer biomarkers, hormone levels, and infectious pathogens. The CLIA systems enable emergency departments, intensive care units, and inpatient services to start treatment without delay through their advanced sensitivity, extensive testing capabilities, and quick result delivery. The move to centralized diagnostic systems, together with automated diagnostic machines, helps hospitals to cut down on manual tasks while achieving better operational results through standardized processes. The worldwide implementation of CLIA analyzers and assays in hospital systems accelerates because hospitals expand their facilities, and preventive health screening programs become more popular, accreditation and quality standards increase, and hospitals need complete laboratory information systems. “APAC is estimated to register the highest CAGR during the forecast period.” The CLIA market in the Asia Pacific region is growing due to three factors: expanding healthcare, rising healthcare spending, and improved distribution of diagnostic services in countries such as China, India, and Southeast Asia. The rising need for precise early diagnostic tests results from the increasing incidence of chronic illnesses, infectious diseases, and conditions linked to lifestyle choices. The government modernization projects, which include hospital upgrades, laboratory automation, and the development of a national screening program, accelerate the implementation of high-throughput CLIA systems. The demand for advanced immunoassay technologies grows due to three factors, which include increasing public knowledge about preventive healthcare, expanding private diagnostic laboratory networks, and rising medical tourism. The regional growth of the market benefits from three factors, which include a large patient base, better insurance access, and the market's shift toward automated laboratory systems that manage high testing loads. The widespread implementation of CLIA platforms throughout APAC results from two factors, which include ongoing international diagnostic company expansion and the rise of affordable domestic manufacturers. Key players in the CLIA market The key players in the market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), DiaSorin S.p.A. (Italy), QuidelOrtho Corporation (US), Sysmex Corporation (Japan), Shenzhen New Industry Biomedical Engineering Co., Ltd. (SNIBE Diagnostics) (China), Tosoh Corporation (Japan), Werfen (Spain), Bio-Rad Laboratories, Inc. (US), Shenzhen Mindray Biomedical Electronics Co., Ltd. (China), Fujirebio (Japan), HUMAN Gesellschaft für Biochemica und Diagnostica mbH. (Germany), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Agappe Diagnostics Ltd (India), Zecen Biotech Co., Ltd (China), Maccura Biotechnology Co., Ltd (China), Autobio Diagnostics Co., Ltd. (China), Artron Laboratories Inc.(Canada), Abnova Corporation (Taiwan), Beijing Hotgen Biotech Co., Ltd (China), and Shanghai Kehua Bio-Engineering Co., Ltd. (China). Research Coverage: The report analyzes the CLIA market and aims at estimating the market size and future growth potential of this market based on various segments such as product type, sample type, technology, application, and end user. The report also includes a product portfolio matrix of various CLIA available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies. Reasons to Buy the Report The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall CLIA market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. This report provides insights into the following pointers: • Analysis of key drivers (increasing incidences of chronic and infectious diseases globally, advancements in improving CLIA technologies in recent years, rapid increase in geriatric population globally, growth of biotechnology and biopharmaceutical industries), restraints (high cost associated with placement and maintenance of CLIA, product recalls and failures), challenges (shortage of skilled professionals, risks associated with CLIAs), and opportunities (growth potential in emerging economies) • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global CLIA market • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global CLIA market • Market Development: Comprehensive information on the lucrative emerging markets by product type, technology, sample type, application, and end user • Market Diversification: Exhaustive information about new products and services or product and service enhancements, growing geographies, recent developments, and investments in the global CLIA market • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global CLIA market
目錄 Table of Contents
1 INTRODUCTION 30 1.1 STUDY OBJECTIVES 30 1.2 MARKET DEFINITION 30 1.3 STUDY SCOPE 31 1.3.1 MARKETS COVERED & REGIONAL SCOPE 31 1.3.2 INCLUSIONS & EXCLUSIONS 32 1.3.3 YEARS CONSIDERED 32 1.3.4 CURRENCY CONSIDERED 33 1.3.5 UNITS CONSIDERED 33 1.4 STAKEHOLDERS 33 1.5 SUMMARY OF CHANGES 34 2 EXECUTIVE SUMMARY 35 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 35 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 36 2.3 DISRUPTIVE TRENDS IN CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET 37 2.4 HIGH-GROWTH SEGMENTS 38 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 39 3 PREMIUM INSIGHTS 41 3.1 CHEMILUMINESCENCE IMMUNOASSAY OVERVIEW 41 3.2 ASIA PACIFIC CHEMILUMINESCENCE IMMUNOASSAY, BY PRODUCT AND COUNTRY 42 3.3 CHEMILUMINESCENCE IMMUNOASSAY: DEVELOPED MARKETS VS. EMERGING ECONOMIES 43 3.4 CHEMILUMINESCENCE IMMUNOASSAY: GEOGRAPHIC GROWTH OPPORTUNITIES 44 3.5 CHEMILUMINESCENCE IMMUNOASSAY: REGIONAL MIX 45 4 MARKET OVERVIEW 46 4.1 INTRODUCTION 46 4.2 MARKET DYNAMICS 47 4.2.1 DRIVERS 47 4.2.1.1 Increasing incidence of chronic and infectious diseases globally 47 4.2.1.2 Advancements in chemiluminescence immunoassay technologies in recent years 49 4.2.1.3 Rapid increase in geriatric population globally 50 4.2.1.4 Growth of biotechnology and biopharmaceutical industries 51 4.2.2 RESTRAINTS 52 4.2.2.1 High cost of chemiluminescence systems and reagents 52 4.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference 52 4.2.3 OPPORTUNITIES 53 4.2.3.1 High growth prospects for players in emerging economies 53 4.2.3.2 Increasing number of collaborations and partnerships 54 4.2.4 CHALLENGES 54 4.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems 54 4.2.4.2 Lack of skilled professionals and aging workforce 55 4.3 UNMET NEEDS & WHITE SPACES 55 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 57 4.4.1 INTERCONNECTED MARKETS 57 4.4.2 CROSS-SECTOR OPPORTUNITIES 58 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 58 5 INDUSTRY TRENDS 60 5.1 PORTER’S FIVE FORCES ANALYSIS 60 5.1.1 THREAT OF NEW ENTRANTS 61 5.1.2 THREAT OF SUBSTITUTES 61 5.1.3 BARGAINING POWER OF SUPPLIERS 62 5.1.4 BARGAINING POWER OF BUYERS 62 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 62 5.2 MACROECONOMIC INDICATORS 62 5.2.1 INTRODUCTION 62 5.2.2 GDP TRENDS & FORECAST 62 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 64 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 65 5.3 VALUE CHAIN ANALYSIS 66 5.4 SUPPLY CHAIN ANALYSIS 67 5.5 ECOSYSTEM ANALYSIS 68 5.6 PRICING ANALYSIS 70 5.6.1 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY KEY PLAYER, 2023–2025 (USD) 71 5.6.2 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY REGION, 2023–2025 (USD) 71 5.6.3 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY TECHNOLOGY, 2023–2025 (USD) 73 5.6.4 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES (KITS, REAGENTS, AND OTHERS), BY SAMPLE TYPE, 2023–2025 (USD) 73 5.7 TRADE ANALYSIS 73 5.7.1 IMPORT DATA FOR HS CODE 9027.89, 2021–2025 74 5.7.2 EXPORT DATA FOR HS CODE 9027.89, 2021–2025 74 5.8 KEY CONFERENCES & EVENTS, 2026–2027 75 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 76 5.10 INVESTMENT & FUNDING SCENARIO 77 5.11 CASE STUDY ANALYSIS 78 5.11.1 CASE STUDY 1: ROCHE COBAS CLIA DRIVES HIGH-VOLUME TESTING PERFORMANCE 78 5.11.2 CASE STUDY 2: ABBOTT ARCHITECT DRIVES REGIONAL MULTI-CENTER LAB EXPANSION 78 5.11.3 CASE STUDY 3: SIEMENS ADVIA CENTAUR XP BOOSTS GOVERNMENT LAB TESTING EFFICIENCY 79 5.12 IMPACT OF 2025 US TARIFFS ON CHEMILUMINESCENCE IMMUNOASSAY MARKET 79 5.12.1 INTRODUCTION 79 5.12.2 KEY TARIFF RATES 80 5.12.3 PRICE IMPACT ANALYSIS 81 5.12.4 IMPACT ON COUNTRIES/REGIONS 81 5.12.4.1 US 81 5.12.4.2 Europe 81 5.12.4.3 Asia Pacific 82 5.12.5 IMPACT ON END-USE INDUSTRIES 82 5.12.5.1 Hospitals 82 5.12.5.2 Clinical laboratories 82 5.12.5.3 Pharmaceutical & biotechnology companies and contract research organizations 83 6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION 84 6.1 TECHNOLOGY ANALYSIS 84 6.1.1 KEY EMERGING TECHNOLOGIES 84 6.1.1.1 Nano-engineered chemiluminescent labels 84 6.1.1.2 Digital immunoassay platforms 84 6.1.2 COMPLEMENTARY TECHNOLOGIES 84 6.1.2.1 Bead-based & microarray chemiluminescence 84 6.1.2.2 Integration with microfluidic platforms 85 6.1.3 ADJACENT TECHNOLOGIES 85 6.1.3.1 Enzyme-linked immunosorbent assay (ELISA) 85 6.2 TECHNOLOGY/PRODUCT ROADMAP 85 6.3 PATENT ANALYSIS 86 6.3.1 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS, AND JURISDICTION FOR CHEMILUMINESCENCE IMMUNOASSAY MARKET, JANUARY 2015–SEPTEMBER 2025 86 6.3.2 LIST OF MAJOR PATENTS, 2022–2025 88 6.4 FUTURE APPLICATIONS 89 6.4.1 PERSONALIZED & PRECISION MEDICINE 89 6.4.2 REMOTE MONITORING & DECENTRALIZED TESTING 89 6.4.3 PREDICTIVE DIAGNOSTICS & CLINICAL DECISION SUPPORT 89 6.4.4 INTEGRATION WITH DIGITAL HEALTH ECOSYSTEMS 89 6.4.5 NEXT-GENERATION BIOMARKER DISCOVERY & MULTIPLEX TESTING 90 6.5 IMPACT OF GEN AI ON CHEMILUMINESCENCE IMMUNOASSAY MARKET 90 6.5.1 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 92 6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 92 6.6.1 IMPROVED OUTCOMES IN CRITICAL CARE & EMERGENCY DIAGNOSTICS 92 6.6.2 PUBLIC HEALTH SCREENING & INFECTIOUS DISEASE CONTROL 92 6.6.3 ENDOCRINOLOGY & CHRONIC DISEASE MANAGEMENT 93 6.6.4 ONCOLOGY DIAGNOSTICS & THERAPY MONITORING 93 6.6.5 MATERNAL & NEONATAL SCREENING PROGRAMS 93 6.6.6 DECENTRALIZED & MID-VOLUME LABORATORY ADOPTION 93 6.6.7 REAL-WORLD IMPACT 93 7 SUSTAINABILITY & REGULATORY LANDSCAPE 94 7.1 REGULATORY LANDSCAPE 94 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 7.1.2 INDUSTRY STANDARDS 97 7.1.2.1 ISO 15189 – Quality & competence requirements for medical laboratories 97 7.1.2.2 CLSI Guidelines (Clinical & Laboratory Standards Institute) – Immunoassay performance & validation 97 7.1.2.3 ISO 13485 – Quality management systems for IVD manufacturers 97 7.1.2.4 ISO 17511 – Metrological traceability of calibrators & control materials 97 7.2 SUSTAINABILITY INITIATIVES 97 7.2.1 REAGENT PACKAGING REDUCTION & RECYCLABLE MATERIALS (INDUSTRY INITIATIVES) 98 7.2.2 ENERGY-EFFICIENT & LOW-WASTE ANALYZER OPERATIONS 98 7.2.3 LABORATORY WASTE MANAGEMENT & GREEN LAB PROGRAMS 98 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 98 7.3.1 CERTIFICATIONS & LABELING STANDARDS 98 7.3.2 ECO-STANDARDS & SUSTAINABILITY CONSIDERATIONS 99 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100 8.1 DECISION-MAKING PROCESS 100 8.2 KEY STAKEHOLDERS & BUYING CRITERIA 101 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 101 8.2.1.1 Influence of stakeholders on buying process for product types 101 8.2.2 BUYING CRITERIA 102 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 103 8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS 104 8.5 MARKET PROFITABILITY 105 8.5.1 REVENUE POTENTIAL 105 8.5.2 COST DYNAMICS 105 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 105 9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE 106 9.1 INTRODUCTION 107 9.2 CONSUMABLES 107 9.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST MARKET SHARE DURING STUDY PERIOD 107 9.3 INSTRUMENTS 109 9.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET 109 10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY 113 10.1 INTRODUCTION 114 10.2 CHEMILUMINESCENCE ENZYME IMMUNOASSAYS 114 10.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET 114 10.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAYS 116 10.3.1 RISING DEMAND FOR HIGH-SENSITIVITY CARDIAC AND ONCOLOGY BIOMARKERS TO DRIVE MARKET 116 10.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAYS 118 10.4.1 SUPERIOR SENSITIVITY AND EARLY DISEASE DETECTION TO DRIVE MARKET GROWTH 118 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE 120 11.1 INTRODUCTION 121 11.2 BLOOD 121 11.2.1 RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET 121 11.3 URINE 122 11.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET 122 11.4 SALIVA 124 11.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET 124 11.5 OTHER SAMPLE TYPES 125 12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION 126 12.1 INTRODUCTION 127 12.2 INFECTIOUS DISEASES 128 12.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 128 12.3 ENDOCRINOLOGY 129 12.3.1 RISING INCIDENCES OF DIABETES TO PROPEL DEMAND FOR DIAGNOSTICS 129 12.4 ONCOLOGY 131 12.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET 131 12.5 CARDIOLOGY 133 12.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET 133 12.6 ALLERGY DIAGNOSTICS 135 12.6.1 GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS 135 12.7 BLOOD SCREENING 136 12.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET 136 12.8 AUTOIMMUNE DISORDERS 138 12.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET 138 12.9 BONE & MINERAL DISORDERS 140 12.9.1 HIGH DISORDER PREVALENCE TO OFFER STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS 140 12.10 TOXICOLOGY 142 12.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET 142 12.11 NEWBORN SCREENING 144 12.11.1 ROUTINE USE IN FIRST-TIER NEWBORN SCREENING PROTOCOL TO SUSTAIN DEMAND 144 12.12 THERAPEUTIC DRUG MONITORING 145 12.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET 145 12.13 METABOLIC DISORDERS 147 12.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET 147 12.14 GASTROENTEROLOGY 149 12.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET 149 12.15 NEUROLOGY 150 12.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT 150 12.16 RESPIRATORY DISEASES 152 12.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET 152 12.17 OTHER APPLICATIONS 153 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER 155 13.1 INTRODUCTION 156 13.2 HOSPITALS 156 13.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES ENSURE LEADERSHIP OF HOSPITALS 156 13.3 CLINICAL LABORATORIES 159 13.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT 159 13.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS 160 13.4.1 RISING DRUG DISCOVERY ACTIVITY AND CLINICAL STUDIES TO DRIVE MARKET 160 13.5 OTHER END USERS 162 14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION 164 14.1 INTRODUCTION 165 14.1.1 GLOBAL: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024–2031 (HUNDRED UNITS) 165 14.2 NORTH AMERICA 166 14.2.1 MACROECONOMIC OUTLOOK 166 14.2.2 NORTH AMERICA: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024–2031 (HUNDRED UNITS) 169 14.2.3 US 172 14.2.3.1 US to hold largest share of North American market during forecast period 172 14.2.4 CANADA 176 14.2.4.1 Rising government initiatives and funding for early disease diagnosis to drive market 176 14.3 EUROPE 181 14.3.1 MACROECONOMIC OUTLOOK 182 14.3.2 EUROPE: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024–2031 (HUNDRED UNITS) 184 14.3.3 GERMANY 187 14.3.3.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market 187 14.3.4 FRANCE 192 14.3.4.1 Favorable reimbursement policies and increased investments in diagnostics to drive market 192 14.3.5 UK 197 14.3.5.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market 197 14.3.6 ITALY 202 14.3.6.1 Growing geriatric population and increasing support for research to drive market 202 14.3.7 SPAIN 206 14.3.7.1 Rising adoption of technologically advanced immunoassay systems to drive market 206 14.3.8 REST OF EUROPE 210 14.4 ASIA PACIFIC 214 14.4.1 MACROECONOMIC OUTLOOK 215 14.4.2 ASIA PACIFIC: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024–2031 (HUNDRED UNITS) 218 14.4.3 JAPAN 221 14.4.3.1 Growing investments in clinical diagnostics research to drive market 221 14.4.4 CHINA 225 14.4.4.1 China to register highest growth rate in Asia Pacific market during study period 225 14.4.5 INDIA 230 14.4.5.1 Growing medical tourism and healthcare infrastructure to drive market 230 14.4.6 SOUTH KOREA 234 14.4.6.1 Rising healthcare spending for innovative IVD technologies to drive market 234 14.4.7 AUSTRALIA 238 14.4.7.1 Rising healthcare spending for innovative IVD technologies to drive market 238 14.4.8 REST OF ASIA PACIFIC 242 14.5 LATIN AMERICA 246 14.5.1 MACROECONOMIC OUTLOOK 247 14.5.2 LATIN AMERICA: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024–2031 (HUNDRED UNITS) 248 14.5.3 BRAZIL 251 14.5.3.1 Improving healthcare facilities to drive market 251 14.5.4 MEXICO 255 14.5.4.1 Robust healthcare system to drive market growth in Mexico 255 14.5.5 REST OF LATIN AMERICA 259 14.6 MIDDLE EAST & AFRICA 263 14.6.1 MACROECONOMIC OUTLOOK 264 14.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024–2031 (HUNDRED UNITS) 265 14.6.3 GCC COUNTRIES 268 14.6.4 REST OF MIDDLE EAST & AFRICA 272 15 COMPETITIVE LANDSCAPE 277 15.1 OVERVIEW 277 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 277 15.3 REVENUE ANALYSIS, 2021–2025 279 15.4 MARKET SHARE ANALYSIS, 2025 280 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 282 15.5.1 STARS 282 15.5.2 EMERGING LEADERS 283 15.5.3 PERVASIVE PLAYERS 283 15.5.4 PARTICIPANTS 283 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 284 15.5.5.1 Company footprint 284 15.5.5.2 Region footprint 285 15.5.5.3 Product type footprint 286 15.5.5.4 Technology footprint 287 15.5.5.5 Sample type footprint 288 15.5.5.6 Application footprint 289 15.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025 291 15.6.1 PROGRESSIVE COMPANIES 291 15.6.2 RESPONSIVE COMPANIES 291 15.6.3 DYNAMIC COMPANIES 291 15.6.4 STARTING BLOCKS 291 15.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2025 293 15.6.5.1 Detailed list of key start-ups/SMEs 293 15.6.5.2 Competitive benchmarking of key start-ups/SMEs 294 15.7 COMPANY VALUATION AND FINANCIAL METRICS 295 15.8 PRODUCT COMPARISON 296 15.8.1 F. HOFFMANN-LA ROCHE LTD 297 15.8.2 DANAHER CORPORATION 297 15.8.3 ABBOTT 297 15.8.4 SIEMENS HEALTHINEERS AG 297 15.8.5 DIASORIN S.P.A 297 15.9 COMPETITIVE SCENARIO 297 16 COMPANY PROFILES 303 16.1 KEY PLAYERS 303 16.1.1 F. HOFFMANN-LA ROCHE LTD 303 16.1.1.1 Business overview 303 16.1.1.2 Products offered 304 16.1.1.3 Recent developments 305 16.1.1.3.1 Product approvals 305 16.1.1.3.2 Deals 305 16.1.1.4 MnM view 305 16.1.1.4.1 Key strengths/Right to win 305 16.1.1.4.2 Strategic choices 306 16.1.1.4.3 Weaknesses/Competitive threats 306 16.1.2 ABBOTT 307 16.1.2.1 Business overview 307 16.1.2.2 Products offered 308 16.1.2.3 Recent developments 309 16.1.2.3.1 Deals 309 16.1.2.4 MnM view 309 16.1.2.4.1 Key strengths/Right to win 309 16.1.2.4.2 Strategic choices 310 16.1.2.4.3 Weaknesses/Competitive threats 310   16.1.3 SIEMENS HEALTHINEERS AG 311 16.1.3.1 Business overview 311 16.1.3.2 Products offered 312 16.1.3.3 Recent developments 313 16.1.3.3.1 Deals 313 16.1.3.4 MnM view 314 16.1.3.4.1 Key strengths/Right to win 314 16.1.3.4.2 Strategic choices 314 16.1.3.4.3 Weaknesses/Competitive threats 314 16.1.4 DANAHER CORPORATION 315 16.1.4.1 Business overview 315 16.1.4.2 Products offered 316 16.1.4.3 Recent developments 317 16.1.4.3.1 Deals 317 16.1.4.4 MnM view 317 16.1.4.4.1 Key strengths/Right to win 317 16.1.4.4.2 Strategic choices 317 16.1.4.4.3 Weaknesses/Competitive threats 318 16.1.5 DIASORIN S.P.A. 319 16.1.5.1 Business overview 319 16.1.5.2 Products offered 321 16.1.5.3 Recent developments 321 16.1.5.3.1 Product approvals 321 16.1.5.3.2 Deals 321 16.1.5.4 MnM view 322 16.1.5.4.1 Key strengths/Right to win 322 16.1.5.4.2 Strategic choices 322 16.1.5.4.3 Weaknesses/Competitive threats 322 16.1.6 QUIDELORTHO CORPORATION 323 16.1.6.1 Business overview 323 16.1.6.2 Products offered 324 16.1.6.3 Recent developments 325 16.1.6.3.1 Deals 325 16.1.7 SYSMEX CORPORATION 326 16.1.7.1 Business overview 326 16.1.7.2 Products offered 327 16.1.7.3 Recent developments 328 16.1.7.3.1 Product launches 328 16.1.7.3.2 Deals 329   16.1.8 SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. 330 16.1.8.1 Business overview 330 16.1.8.2 Products offered 331 16.1.8.3 Recent developments 332 16.1.8.3.1 Product approvals 332 16.1.9 TOSOH CORPORATION 333 16.1.9.1 Business overview 333 16.1.9.2 Products offered 335 16.1.9.3 Recent developments 336 16.1.9.3.1 Product launches 336 16.1.10 WERFEN 337 16.1.10.1 Business overview 337 16.1.10.2 Products offered 338 16.1.10.3 Recent developments 339 16.1.10.3.1 Deals 339 16.1.11 BIO-RAD LABORATORIES, INC. 340 16.1.11.1 Business overview 340 16.1.11.2 Products offered 341 16.1.11.3 Recent developments 342 16.1.11.3.1 Product launches 342 16.1.12 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 343 16.1.12.1 Business overview 343 16.1.12.2 Products offered 343 16.1.12.3 Recent developments 344 16.1.12.3.1 Deals 344 16.1.13 FUJIREBIO 345 16.1.13.1 Business overview 345 16.1.13.2 Products offered 345 16.1.13.3 Recent developments 346 16.1.13.3.1 Deals 346 16.1.14 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 347 16.1.14.1 Business overview 347 16.1.14.2 Products offered 347 16.1.14.3 Recent developments 348 16.1.14.3.1 Product launches & approvals 348 16.1.14.3.2 Deals 348 16.1.15 AGAPPE DIAGNOSTICS LTD. 349 16.1.15.1 Business overview 349 16.1.15.2 Products offered 349 16.1.15.3 Recent developments 350 16.1.15.3.1 Deals 350   16.2 OTHER PLAYERS 351 16.2.1 ZECEN BIOTECH CO., LTD 351 16.2.2 MACCURA BIOTECHNOLOGY CO., LTD. 352 16.2.3 AUTOBIO DIAGNOSTICS 353 16.2.4 ARTRON LABORATORIES INC. 354 16.2.5 HUMAN GESELLSCHAFT FÜR BIOCHEMICA UND DIAGNOSTICA MBH 355 16.2.6 ABNOVA CORPORATION 356 16.2.7 BEIJING HOTGEN BIOTECH CO., LTD. 357 16.2.8 ELABSCIENCE 358 16.2.9 GETEIN BIOTECH, INC. 359 16.2.10 SHANGHAI KEHUA BIO-ENGINEERING CO., LTD. 360 17 RESEARCH METHODOLOGY 361 17.1 RESEARCH DATA 361 17.1.1 SECONDARY DATA 362 17.1.1.1 Key data from secondary sources 363 17.1.1.2 Primary sources 363 17.1.1.3 Key data from primary sources 364 17.1.1.4 Breakdown of primaries 364 17.2 MARKET SIZE ESTIMATION 365 17.3 GROWTH FORECAST 369 17.4 MARKET BREAKDOWN & DATA TRIANGULATION 370 17.5 RESEARCH ASSUMPTIONS 372 17.6 RESEARCH LIMITATIONS 372 17.7 RISK ASSESSMENT 372 18 APPENDIX 373 18.1 DISCUSSION GUIDE 373 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 378 18.3 CUSTOMIZATION OPTIONS 380 18.3.1 GEOGRAPHIC ANALYSIS 380 18.3.2 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 380 18.3.3 COMPANY INFORMATION 380 18.3.4 PRODUCT TYPE ANALYSIS 380 18.3.4.1 By Analyzer (Semi and fully automated system) 380 18.3.4.2 By Technology (Breakdown by subcategories) 380 18.3.5 BY END USER ((BREAKDOWN BY SUBCATEGORIES) 380 18.3.6 BY MODE OF PURCHASE/BUSINESS MODEL 380 18.3.7 COUNTRY-LEVEL VOLUME ANALYSIS 380 18.3.8 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 380 18.3.9 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 380   18.4 RELATED REPORTS 381 18.5 AUTHOR DETAILS 382
圖表清單 List of Tables & Figures
TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD) 33 TABLE 2 UNMET CUSTOMER NEEDS & WHITE SPACES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 56 TABLE 3 INTERCONNECTED MARKETS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 57 TABLE 4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 59 TABLE 5 CHEMILUMINESCENCE IMMUNOASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 60 TABLE 6 GLOBAL GROSS DOMESTIC PRODUCT AT CURRENT PRICES, 2021–2030 (USD BILLION) 63 TABLE 7 CHEMILUMINESCENCE IMMUNOASSAY MARKET: ROLE IN ECOSYSTEM 69 TABLE 8 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY KEY PLAYER, 2023–2025 (USD) 71 TABLE 9 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY REGION, 2023–2025 (USD) 72 TABLE 10 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY TECHNOLOGY, 2023–2025 (USD) 73 TABLE 11 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES (KITS, REAGENTS, AND OTHERS), BY SAMPLE TYPE, 2023–2025 (USD) 73 TABLE 12 IMPORT DATA FOR HS CODE 9027.89-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 74 TABLE 13 EXPORT DATA FOR HS CODE 901839-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 75 TABLE 14 DETAILED LIST OF CONFERENCES & EVENTS, 2026–2027 75 TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES 80 TABLE 16 CHEMILUMINESCENCE IMMUNOASSAY MARKET: TECHNOLOGY/PRODUCT ROADMAP 86 TABLE 17 CHEMILUMINESCENCE IMMUNOASSAY MARKET: LIST OF MAJOR PATENTS, JANUARY 2022–SEPTEMBER 2025 88 TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95 TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95 TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 TABLE 22 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT TYPES 101 TABLE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 102 TABLE 25 CHEMILUMINESCENCE IMMUNOASSAY MARKET: UNMET NEEDS IN KEY END-USE SETTINGS 104 TABLE 26 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 107 TABLE 27 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE 108 TABLE 28 CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109 TABLE 29 CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS MARKET, 2024–2031 (HUNDRED UNITS) 110 TABLE 30 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE 111 TABLE 31 CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112 TABLE 32 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 114 TABLE 33 CHEMILUMINESCENCE ENZYME IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 34 ELECTROCHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 35 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 36 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 121 TABLE 37 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 38 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 39 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR SALIVA SAMPLES, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 40 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 41 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 127 TABLE 42 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 43 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 44 CANCER INCIDENCE, BY TYPE (2022) 131 TABLE 45 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 132 TABLE 46 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 47 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 48 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 49 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 50 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 51 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR TOXICOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 53 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 54 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR THERAPEUTIC DRUG MONITORING, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 55 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 56 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 58 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 59 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 60 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 156 TABLE 61 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 62 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 63 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 64 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 65 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 165 TABLE 66 CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS MARKET, 2024–2031 (HUNDRED UNITS) 165 TABLE 67 NORTH AMERICA: MACROECONOMIC OUTLOOK 167 TABLE 68 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 69 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 169 TABLE 70 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS MARKET, 2024–2031 (HUNDRED UNITS) 169 TABLE 71 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 170 TABLE 72 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 170 TABLE 73 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 171 TABLE 74 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 172 TABLE 75 US: KEY MACROINDICATORS 173 TABLE 76 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 173 TABLE 77 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 174 TABLE 78 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 174 TABLE 79 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 175 TABLE 80 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 176 TABLE 81 CANADA: ESTIMATED PREVALENCE OF DIABETES 176 TABLE 82 CANADA: KEY MACROINDICATORS (2024) 177 TABLE 83 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 178 TABLE 84 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 178 TABLE 85 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 179 TABLE 86 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 180 TABLE 87 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 181 TABLE 88 EUROPE: MACROECONOMIC OUTLOOK 182 TABLE 89 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 90 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 183 TABLE 91 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS MARKET, 2024–2031 (HUNDRED UNITS) 184 TABLE 92 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 184 TABLE 93 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 185 TABLE 94 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 186 TABLE 95 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 187 TABLE 96 GERMANY: KEY MACROINDICATORS 188 TABLE 97 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 189 TABLE 98 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 189 TABLE 99 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 190 TABLE 100 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 191 TABLE 101 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 192 TABLE 102 FRANCE: KEY MACROINDICATORS (2024) 193 TABLE 103 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 194 TABLE 104 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 194 TABLE 105 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 195 TABLE 106 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 196 TABLE 107 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 197 TABLE 108 UK: KEY MACROINDICATORS 198 TABLE 109 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 199 TABLE 110 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 199 TABLE 111 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 200 TABLE 112 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 201 TABLE 113 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 202 TABLE 114 ITALY: KEY MACROINDICATORS (2024) 203 TABLE 115 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 203 TABLE 116 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 204 TABLE 117 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 204 TABLE 118 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 205 TABLE 119 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 206 TABLE 120 SPAIN: KEY MACROINDICATORS (2024) 207 TABLE 121 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 207 TABLE 122 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 208 TABLE 123 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 208 TABLE 124 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 209 TABLE 125 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 126 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 211 TABLE 127 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 211 TABLE 128 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 212 TABLE 129 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 213 TABLE 130 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 214 TABLE 131 ASIA PACIFIC: MACROECONOMIC OUTLOOK 215 TABLE 132 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 133 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 217 TABLE 134 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS MARKET, 2024–2031 (HUNDRED UNITS) 218 TABLE 135 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 218 TABLE 136 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 219 TABLE 137 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 220 TABLE 138 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 221 TABLE 139 JAPAN: KEY MACROINDICATORS (2024) 222 TABLE 140 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 222 TABLE 141 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 223 TABLE 142 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 223 TABLE 143 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 224 TABLE 144 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 225 TABLE 145 CHINA: KEY MACROINDICATORS (2024) 227 TABLE 146 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 227 TABLE 147 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 228 TABLE 148 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 228 TABLE 149 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 229 TABLE 150 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 230 TABLE 151 INDIA: KEY MACROINDICATORS (2024) 231 TABLE 152 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 231 TABLE 153 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 232 TABLE 154 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 232 TABLE 155 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 233 TABLE 156 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 234 TABLE 157 SOUTH KOREA: KEY MACROINDICATORS (2024) 235 TABLE 158 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 235 TABLE 159 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 236 TABLE 160 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 236 TABLE 161 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 237 TABLE 162 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 238 TABLE 163 AUSTRALIA: KEY MACROINDICATORS (2024) 239 TABLE 164 AUSTRALIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 239 TABLE 165 AUSTRALIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 240 TABLE 166 AUSTRALIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 240 TABLE 167 AUSTRALIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 241 TABLE 168 AUSTRALIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 242 TABLE 169 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 243 TABLE 170 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 243 TABLE 171 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 244 TABLE 172 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 245 TABLE 173 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 174 LATIN AMERICA: MACROECONOMIC OUTLOOK 247 TABLE 175 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 176 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 248 TABLE 177 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS MARKET, 2024–2031 (HUNDRED UNITS) 248 TABLE 178 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 249 TABLE 179 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 249 TABLE 180 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 250 TABLE 181 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 251 TABLE 182 BRAZIL: KEY MACROINDICATORS (2024) 252 TABLE 183 BRAZIL: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 252 TABLE 184 BRAZIL: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 253 TABLE 185 BRAZIL: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 253 TABLE 186 BRAZIL: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 254 TABLE 187 BRAZIL: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 255 TABLE 188 MEXICO: KEY MACROINDICATORS (2024) 256 TABLE 189 MEXICO: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 256 TABLE 190 MEXICO: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 257 TABLE 191 MEXICO: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 257 TABLE 192 MEXICO: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 258 TABLE 193 MEXICO: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 194 REST OF LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 260 TABLE 195 REST OF LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 260 TABLE 196 REST OF LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 261 TABLE 197 REST OF LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 262 TABLE 198 REST OF LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 263 TABLE 199 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 264 TABLE 200 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 264 TABLE 201 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 265 TABLE 202 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS MARKET, 2024–2031 (HUNDRED UNITS) 265 TABLE 203 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 266 TABLE 204 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 266 TABLE 205 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 267 TABLE 206 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 268 TABLE 207 GCC COUNTRIES: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 269 TABLE 208 GCC COUNTRIES: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 269 TABLE 209 GCC COUNTRIES: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 270 TABLE 210 GCC COUNTRIES: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 271 TABLE 211 GCC COUNTRIES: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 272 TABLE 212 REST OF MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 273 TABLE 213 REST OF MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 273 TABLE 214 REST OF MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 274 TABLE 215 REST OF MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 275 TABLE 216 REST OF MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 276 TABLE 217 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET, JANUARY 2023–JANUARY 2026 278 TABLE 218 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEGREE OF COMPETITION, 2025 281 TABLE 219 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REGION FOOTPRINT 285 TABLE 220 CHEMILUMINESCENCE IMMUNOASSAY MARKET: PRODUCT TYPE FOOTPRINT 286 TABLE 221 CHEMILUMINESCENCE IMMUNOASSAY MARKET: TECHNOLOGY FOOTPRINT 287 TABLE 222 CHEMILUMINESCENCE IMMUNOASSAY MARKET: SAMPLE TYPE FOOTPRINT 288 TABLE 223 CHEMILUMINESCENCE IMMUNOASSAY MARKET: APPLICATION FOOTPRINT 289 TABLE 224 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES 293 TABLE 225 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 294 TABLE 226 CHEMILUMINESCENCE IMMUNOASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JANUARY 2026 298 TABLE 227 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEALS, JANUARY 2023–JANUARY 2026 300 TABLE 228 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 303 TABLE 229 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 304 TABLE 230 F. HOFFMANN-LA ROCHE LTD: PRODUCT APPROVALS, JANUARY 2023–JANUARY 2026 305 TABLE 231 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2023–JANUARY 2026 305 TABLE 232 ABBOTT: COMPANY OVERVIEW 307 TABLE 233 ABBOTT: PRODUCTS OFFERED 308 TABLE 234 ABBOTT: DEALS, JANUARY 2023–JANUARY 2026 309 TABLE 235 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 311 TABLE 236 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 312 TABLE 237 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023–JANUARY 2026 313 TABLE 238 DANAHER CORPORATION: COMPANY OVERVIEW 315 TABLE 239 DANAHER CORPORATION: PRODUCTS OFFERED 316 TABLE 240 DANAHER CORPORATION: DEALS, JANUARY 2023–JANUARY 2026 317 TABLE 241 DIASORIN S.P.A.: COMPANY OVERVIEW 319 TABLE 242 DIASORIN S.P.A.: PRODUCTS OFFERED 321 TABLE 243 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2023–JANUARY 2026 321 TABLE 244 DIASORIN S.P.A.: DEALS, JANUARY 2023–JANUARY 2026 321 TABLE 245 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 323 TABLE 246 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 324 TABLE 247 QUIDELORTHO CORPORATION: DEALS, JANUARY 2023–JANUARY 2026 325 TABLE 248 SYSMEX CORPORATION: COMPANY OVERVIEW 326 TABLE 249 SYSMEX CORPORATION: PRODUCTS OFFERED 327 TABLE 250 SYSMEX CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–JANUARY 2026 328 TABLE 251 SYSMEX CORPORATION: DEALS, JANUARY 2023–JANUARY 2026 329 TABLE 252 SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.: COMPANY OVERVIEW 330 TABLE 253 SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.: PRODUCTS OFFERED 331 TABLE 254 SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.: PRODUCT APPROVALS, JANUARY 2023–JANUARY 2026 332 TABLE 255 TOSOH CORPORATION: COMPANY OVERVIEW 333 TABLE 256 TOSOH CORPORATION: PRODUCTS OFFERED 335 TABLE 257 TOSOH CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–JANUARY 2026 336 TABLE 258 WERFEN: COMPANY OVERVIEW 337 TABLE 259 WERFEN: PRODUCTS OFFERED 338 TABLE 260 WERFEN: DEALS, JANUARY 2023–JANUARY 2026 339 TABLE 261 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 340 TABLE 262 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 341 TABLE 263 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023–JANUARY 2026 342 TABLE 264 SHENZHEN MINDRAY BIOMEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 343 TABLE 265 SHENZHEN MINDRAY BIOMEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 343 TABLE 266 SHENZHEN MINDRAY BIOMEDICAL ELECTRONICS CO., LTD.: DEALS, JANUARY 2023–JANUARY 2026 344 TABLE 267 FUJIREBIO: COMPANY OVERVIEW 345 TABLE 268 FUJIREBIO: PRODUCTS OFFERED 345 TABLE 269 FUJIREBIO: DEALS, JANUARY 2023–JANUARY 2026 346 TABLE 270 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW 347 TABLE 271 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: PRODUCTS OFFERED 347 TABLE 272 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JANUARY 2026 348 TABLE 273 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: DEALS, JANUARY 2023–JANUARY 2026 348 TABLE 274 AGAPPE DIAGNOSTICS LTD.: COMPANY OVERVIEW 349 TABLE 275 AGAPPE DIAGNOSTICS LTD.: PRODUCTS OFFERED 349 TABLE 276 AGAPPE DIAGNOSTICS LTD.: DEALS, JANUARY 2023–JANUARY 2026 350 TABLE 277 ZECEN BIOTECH CO., LTD: COMPANY OVERVIEW 351 TABLE 278 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 352 TABLE 279 AUTOBIO DIAGNOSTICS: COMPANY OVERVIEW 353 TABLE 280 ARTRON LABORATORIES INC.: COMPANY OVERVIEW 354 TABLE 281 HUMAN GESELLSCHAFT FÜR BIOCHEMICA UND DIAGNOSTICA MBH: COMPANY OVERVIEW 355 TABLE 282 ABNOVA CORPORATION: COMPANY OVERVIEW 356 TABLE 283 BEIJING HOTGEN BIOTECH CO., LTD.: COMPANY OVERVIEW 357 TABLE 284 ELABSCIENCE: COMPANY OVERVIEW 358 TABLE 285 GETEIN BIOTECH, INC.: COMPANY OVERVIEW 359 TABLE 286 SHANGHAI KEHUA BIO-ENGINEERING CO., LTD.: COMPANY OVERVIEW 360 FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE 31 FIGURE 2 MARKET SCENARIO 35 FIGURE 3 GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET, 2024–2031 36 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET, 2023–2026 36 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET 37 FIGURE 6 HIGH-GROWTH SEGMENTS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET, 2026–2031 38 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN THE CHEMILUMINESCENCE IMMUNOASSAY MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 39 FIGURE 8 TECHNOLOGICAL ADVANCEMENTS IN MEDICAL DEVICE MODALITIES TO DRIVE THE MARKET 41 FIGURE 9 CHINA AND CONSUMABLES TO DOMINATE APAC MARKET IN 2025 42 FIGURE 10 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 43 FIGURE 11 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 44 FIGURE 12 NORTH AMERICA TO DOMINATE MARKET IN 2030 45 FIGURE 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47 FIGURE 14 GLOBAL DIABETES INCIDENCE, 2021 VS. 2045 (MILLION) 48 FIGURE 15 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995–2030 (MILLION INDIVIDUALS) 49 FIGURE 16 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION) 51 FIGURE 17 CHEMILUMINESCENCE IMMUNOASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 61 FIGURE 18 CHEMILUMINESCENCE IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS (2025) 66 FIGURE 19 CHEMILUMINESCENCE IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS (2025) 68 FIGURE 20 CHEMILUMINESCENCE IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS, 2025 69 FIGURE 21 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY REGION, 2023–2025 (USD) 72 FIGURE 22 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 76 FIGURE 23 INVESTMENT/VENTURE CAPITAL SCENARIO IN CHEMILUMINESCENCE IMMUNOASSAY MARKET, 2022–2025 77 FIGURE 24 PATENT PUBLICATION TRENDS, JURISDICTION, AND TOP APPLICANT ANALYSIS (JANUARY 2015–DECEMBER 2025) 87 FIGURE 25 TOP APPLICANT COUNTRIES/REGIONS FOR CHEMILUMINESCENCE IMMUNOASSAY PATENTS (JANUARY 2015–DECEMBER 2025) 88 FIGURE 26 MARKET POTENTIAL OF AI/GEN AI ON CLIA ACROSS END USERS 90 FIGURE 27 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 92 FIGURE 28 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DECISION-MAKING FACTORS 101 FIGURE 29 KEY BUYING CRITERIA FOR TOP THREE END USERS 102 FIGURE 30 ADOPTION BARRIERS & INTERNAL CHALLENGES 103 FIGURE 31 GLOBAL INCIDENCE OF DIABETES 147 FIGURE 32 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT 168 FIGURE 33 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT 216 FIGURE 34 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REVENUE ANALYSIS OF TOP FIVE PLAYERS, 2021–2025 279 FIGURE 35 MARKET SHARE ANALYSIS OF COMPANIES OFFERING CHEMILUMINESCENCE IMMUNOASSAYS, 2025 280 FIGURE 36 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 283 FIGURE 37 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY FOOTPRINT 284 FIGURE 38 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025 292 FIGURE 39 5-YEAR STOCK BETA OF KEY VENDORS 295 FIGURE 40 FINANCIAL METRICS (EV/EBITDA) 295 FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAYS: PRODUCT COMPARATIVE ANALYSIS 296 FIGURE 42 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 304 FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025) 308 FIGURE 44 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 312 FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 316 FIGURE 46 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 320 FIGURE 47 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025) 324 FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025) 327 FIGURE 49 SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.: COMPANY SNAPSHOT (2024) 331 FIGURE 50 TOSOH CORPORATION: COMPANY SNAPSHOT (2025) 334 FIGURE 51 WERFEN: COMPANY SNAPSHOT (2024) 338 FIGURE 52 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 341 FIGURE 53 RESEARCH DESIGN 361 FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 364 FIGURE 55 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 365 FIGURE 56 MARKET SIZE ESTIMATION PROCESS 366 FIGURE 57 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025) 367 FIGURE 58 CHEMILUMINESCENCE IMMUNOASSAY MARKET: SUPPLY-SIDE ANALYSIS 367 FIGURE 59 TOP-DOWN APPROACH 368 FIGURE 60 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET (2026–2031) 369 FIGURE 61 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY MARKET (2025) 370 FIGURE 62 DATA TRIANGULATION 371

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們